Objective: Although individual neonatal epilepsy syndromes are rare, as a group they represent a sizable subgroup of neonatal seizure etiologies. We evaluated the profile of neonatal epilepsies in a prospective cohort of newborns with seizures.
Although most seizures in the neonatal period reflect acute, acquired brain dysfunction, a substantial minority of newborns with seizures have a neonatal-onset epilepsy. Early differentiation of acute symptomatic seizures from neonatal-onset epilepsies has important therapeutic and prognostic implications since the evaluation and long-term management of neonatal epilepsies are distinct from those of acute symptomatic seizures. Many neonatal epilepsy syndromes have a genetic etiology 1, 2 and some may be amenable to targeted therapy. 3 For example, recent studies have shown that oral carbamazepine, a sodium channel blocker seldom used in newborns, is safe and effective in KCNQ2-related neonatal epilepsies, even in the context of status epilepticus. 4, 5 Other syndromes, such as pyridoxine-dependent epilepsy, have clearly defined and specific treatments. 6, 7 In addition, the prognosis of many neonatal epilepsies is unfavorable, with the notable exception of benign familial neonatal epilepsy (BFNE). 2 Since neonatal seizures are relatively rare, 8, 9 and neonatal epilepsies are even less common, effective clinical research on this topic requires multicenter collaboration. We aimed to determine the proportion of newborns who have neonatal-onset epilepsy, rather than acute symptomatic seizures, among all newborns who present with seizures to tertiary care children's hospitals. Further, we aimed to identify the clinical characteristics, etiologies, and initial treatments prescribed for a contemporary prospective cohort of newborns with neonatal epilepsies who were treated at 1 of 7 US tertiary children's hospitals.
METHODS Standard protocol approvals, registrations, and patient consents. The Neonatal Seizure Registry is an association of 7 US neonatal neurology programs with level IV neonatal intensive care units that were selected based on their adherence to the American Clinical Neurophysiology Society (ACNS) guideline on neonatal EEG monitoring. 10 Each center obtained institutional review board approval and a waiver of informed consent was granted for this study.
Patients. Every newborn with a clinical or EEG diagnosis of seizures treated at 1 of the 7 participating tertiary children's hospitals between January 2013 and November 2015 was prospectively enrolled in the Neonatal Seizure Registry. The clinical profile of a subset of newborns with acute symptomatic seizures has been presented previously. 11 Prospective, systematic medical record review was conducted by a research assistant and an investigator at each study site. In addition, the Registry principal investigator (H.C.G.) reviewed a random sample of 5 charts from each center to insure data integrity and consistent data abstraction across sites.
Newborns were considered to have neonatal epilepsy, and included in the present analysis, if the study site investigator indicated that they had any of the following: (1) a clinical diagnosis of neonatal epileptic encephalopathy (no developmental brain abnormality, history incompatible with benign neonatal seizures or BFNE, and lack of primary acute symptomatic etiology), (2) a congenital brain malformation as the seizure etiology (e.g., lissencephaly, focal malformation of cortical development, holoprosencephaly), or (3) a clinical diagnosis of BFNE or benign neonatal seizures. Neonates with epilepsy and a comorbid illness that predisposed to acute symptomatic seizures were included.
Evaluation (e.g., EEG, neuroimaging, and genetic testing) and treatment (including medication selection, dosing, and duration of treatment) were conducted at the discretion of the clinical teams and were not mandated by a research protocol. Data regarding evaluation for etiology, treatment, and hospital outcomes (e.g., death or discharge to home) are presented.
Counseling and consent for genetic testing were conducted by the treating clinicians and the available clinical result reports were evaluated by the investigators. Single nucleotide variants and small indels were identified using commercial gene panels or Sanger sequencing. Whole exome sequencing was used in a subset of cases. Copy number variations were identified using genomic single nucleotide polymorphism arrays or comprehensive genomic hybridization arrays. The variants detected were queried against the Exome Variant Server database (evs.gs. washington.edu) in order to determine their prevalence in large control populations. Polyphen-2 software (genetics.bwh.harvard. edu/pph2) was used to determine in silico likelihood of pathogenicity. Clinical significance of variants and inheritance patterns were queried using the ClinVar (ncbi.nlm.nih.gov/clinvar) and OMIM (ncbi.nlm.nih.gov/omim) databases.
EEG monitoring was performed according to the ACNS guideline. 10 Neonatal epileptic encephalopathies. Thirty-five newborns (20 male, estimated gestational age [EGA] 39.4 6 1.2 weeks) had neonatal epileptic encephalopathy syndromes (tables 2 and 3). Four had a documented clinical diagnosis of Ohtahara syndrome and one had early myoclonic epilepsy. The others were not assigned a classic epilepsy syndrome by their treating clinicians. Among the 31 for whom the information was documented, 22 received at least one dose of pyridoxine, folinic acid, or pyridoxyl-5-phosphate, although none was ultimately diagnosed with vitamin-dependent epilepsy.
Most (29/35 [83%]) had genetic testing performed on a clinical basis. The majority of those tested had a genetic etiology identified (24/29 [83%]). Of these, pathogenic or likely pathogenic variants in KCNQ2 were the most common (n 5 10, of whom 1 also had a 15q11.2 deletion). Three infants had SCN2a variants, and 1 each had variants in SLC13A5, STXBP1, KCNT1, GDLC, CDKL5, CHD7, MBD5, and TSC2 genes. One newborn had variants in both SCN1a and GRIN2B; 1 had variants in COQ4 as well as MARS and SLC2A8; and 1 had a large deletion at 16p13.11. Details of the genetic test results are presented in table e-1 at Neurology.org.
Clinicians most commonly ordered an epilepsy gene panel (15 of 23 completed gene panels were diagnostic of a genetic epilepsy). Chromosomal microarray was completed for 12 neonates and revealed the cause of the epilepsy in 2. Whole exome sequencing was diagnostic for 2 of the 3 individuals for whom it was performed (1 with a KCNQ2 variant and 1 with a SLC13A5 variant). Single gene testing was obtained for 9 newborns, and 5 confirmed the suspected diagnosis (2 KCNQ2, 1 TSC2, 1 GDLC, 1 CDH7). Two infants had comorbid sepsis and 1 had hypocalcemia.
Three of these newborns died during the neonatal admission and 3 others were transferred to a different hospital for continued care. The remaining 29 (83%) survived to discharge home. These infants were prescribed a median of 1 antiseizure medication at the time of discharge (range 0-6 Thirty-two newborns (12 male, EGA 37.5 6 2.7 weeks) had epilepsy due to congenital brain malformations. The most common malformations were neuronal migration abnormalities (5 lissencephaly, including 1 with associated congenital muscular dystrophy; 3 polymicrogyria; 3 focal cortical dysplasia; 2 schizencephaly, including 1 with associated polymicrogyria; 1 pachygyria; 1 subependymal gray matter heterotopia). Two had hemimegalencephaly, 5 had Dandy-Walker malformations, 3 had holoprosencephaly, and 1 had septo-optic dysplasia. Fifteen had no extracerebral congenital anomalies, while 17 had a range of congenital abnormalities (including 7 congenital heart disease, 2 myelomeningocele, 1 tracheal-esophageal fistula, 1 omphalocele, and 2 congenital glaucoma). Ten (31%) also had a comorbid acute symptomatic seizure etiology (3 hypoxic-ischemic encephalopathy, 2 parenchymal hemorrhages, 2 subdural hematoma, 1 CNS infection, and 2 comorbid peroxisomal disorders, 1 of whom also had sepsis). Comorbid acute illnesses that predisposed to acute symptomatic seizures were more common among newborns with brain (table 2 and table  e-1) , and 6 of these had a defined genetic diagnosis (1 each had TUBA1A, DCX, SETBP1, LAMB1, Emmanuel syndrome, and 15q11.1 duplication). Twenty infants had a chromosomal microarray (1 with abnormalities thought to explain the epilepsy: 15q11.1 duplication). A gene panel was diagnostic in 3 of 4 infants (TUBA1A, DCX, LAMB1). Single gene testing was also diagnostic for 1 of 2 infants (SETBP1). Whole exome sequencing was performed for 2 patients; the result was negative for 1 infant and revealed homozygosity at 7q21.11 to q31.33, which encompasses RELN, and might explain the brain malformation and epilepsy for 1 infant.
None of the neonates with brain malformation was given a clinical diagnosis of Ohtahara syndrome or early myoclonic epilepsy by the treating clinicians.
Eight neonates with epilepsy related to brain malformations did not have seizures recorded at the study center; 1 of these had documented EEG seizures at a referring hospital and the others had seizures diagnosed based on clinical semiologies prior to EEG monitoring (4 focal multifocal clonic, 2 bilateral tonic, 1 focal clonic, 4 other). Additional EEG and seizure semiology data are presented in table 3.
Neonates with epilepsy related to brain malformations were more likely to die (n 5 7) or to be discharged to hospice care (n 5 4) than those with epileptic encephalopathies (n 5 3 died and none discharged to hospice; p 5 0.01). Six were transferred to a local hospital for continued care. The 15 who survived to discharge home were prescribed a median of 2 antiseizure medications at the time of discharge (range 0-7). Medications at the time of discharge to home or transfer to a different hospital for ongoing care included phenobarbital (17 DISCUSSION Neonatal-onset epilepsies cause an important minority of neonatal seizures and present major diagnostic and therapeutic challenges. Our data indicate that identifiable genetic etiologies are responsible for many neonatal epilepsies; more than three-quarters of those who underwent testing had abnormalities identified. In addition, neonatal seizures due to epilepsy presented most often as clinically apparent events and required more than one antiseizure medication, as opposed to the more common subclinical (EEG-only) seizures recorded for newborns with acute symptomatic etiologies. Notably, nearly one-third of newborns with brain malformations as their primary seizure etiology had coexisting illnesses that also predisposed them to acute symptomatic seizures (hypoxic-ischemic encephalopathy, infection); this highlights the need for comprehensive diagnostic evaluations for all newborns with seizures.
Neonatal-onset epilepsies have a broad spectrum of phenotypes that ranges from relatively benign to much more severe. Genetic etiologies are being discovered for a growing proportion of these disorders, and this has helped to elucidate their molecular mechanisms. 13 We demonstrate here that newborns with epilepsy very often have an identifiable genetic etiology. In the past, genetic testing could provide a diagnosis but did not alter treatment for most individuals; however, the role of genetic testing as a guide for treatment strategies is expanding. Several recent studies 3,4,14 have highlighted the importance of accurate phenotype definition and seizure characterization in the neonatal period in order to expedite early diagnosis. Advances in diagnostic testing raise the important possibility of targeted treatment designed to improve seizure control and potentially improve long-term neurodevelopment. Finally, genetic testing may provide important long-term prognostic information for families to guide overall short-and long-term management, and to inform recurrence risk for future pregnancies.
Our multicenter prospective study gathered clinical data from the neonatal hospitalization of more than 600 consecutive newborns with seizures. Yet not every neonatal epilepsy syndrome or etiology was represented in this cohort. For example, there were no identified cases of vitamin-responsive epilepsy, even though more than two-thirds of neonates with epileptic encephalopathy received trials of pyridoxine, folinic acid, or pyridoxal-5-phosphate. This underscores the need for extensive multicenter collaborations for the study of rare neonatal epilepsies.
The classic neonatal epileptic encephalopathy syndromes 15 were rarely identified by name in these patients' medical records. Only 4 were diagnosed with Ohtahara syndrome and just one with early myoclonic encephalopathy by their treating clinicians. This may be related to improving identification of the genetic underpinnings of many neonatal epilepsies such that newborns were given a specific genetic diagnosis (e.g., KCNQ2 encephalopathy) rather than the broader epileptic encephalopathy syndrome diagnosis. All 7 study sites have level IV neonatal intensive care units and provide state-of-the-art neuromonitoring and clinical epilepsy care. All sites follow the ACNS guidelines for neonatal EEG monitoring, which includes conventional video-EEG throughout cooling and rewarming for neonates treated with therapeutic hypothermia for hypoxic-ischemic encephalopathy. 10 This might explain why the duration of EEG monitoring was longer among neonates with acute symptomatic seizures than in those with epilepsy (hypoxic-ischemic encephalopathy was the most common cause of acute symptomatic seizures in this cohort 11 ). In addition, neonates with epilepsy were less likely to have subclinical seizures than were those with acute symptomatic etiologies. This also likely contributed to the difference in EEG monitoring duration between the groups, since all centers monitor the majority of neonates until both electroclinical and subclinical (EEG-only) seizures have resolved for at least 24 hours.
A strength of our work is that we present realworld clinical data regarding a large number of monitoring reports. EEG background classification was assigned according to a published system ("best" background was the least abnormal pattern described, while "most abnormal" background was the most severe pattern described in the clinical report). newborns with epilepsy. Our study has some limitations related to its clinically based design. The study sites did not use uniform guidelines for diagnostic evaluations or treatment of seizures. All newborns with epilepsy had a brain MRI study, but the interpretation was performed locally by a pediatric neuroradiologist and confirmed by the study investigators rather than by a central neuroradiologist. EEG background characteristics and seizure assessments were extracted from clinical reports by the study investigators rather than by a central electroencephalographer. Genetic testing was undertaken at the clinicians' discretion and within the constraints of local policies regarding insurance reimbursement. Therefore, the approach to genetic testing was not consistent across study sites and the specific details of detected genetic variants were not uniformly available. Parental testing was not always obtained and this complicates the interpretation of some patients' results. It is possible that increased use of genetic testing would have identified an even greater number of neonates with a genetic basis for their epilepsy. It is also possible that, in time, variants that are currently determined to be of uncertain significance will be reclassified as pathogenic or as benign.
The gene discovery efforts of the last decade, particularly for the early-onset epileptic encephalopathies, have shown that genetic variants play a major etiologic role and should often be considered in the differential diagnosis of seizures in newborns and infants. 16, 17 However, many unresolved questions remain. The electroclinical presentation of some neonatal-onset epilepsies is not yet well-defined since many patients are only diagnosed in retrospect, when documented clinical and EEG findings related to the neonatal period may be scarce. In addition, variants in a single gene (e.g., KCNQ2) can be associated with both relatively benign and severe epilepsies. Yet our data suggest that a focused effort to increase access to clinical genetic testing for newborns with epilepsy may have far-reaching implications since a putative genetic etiology was found for three-quarters of newborns who were tested. Targeted treatments could eventually be provided to those with genetically proven etiologies and early effective treatment may improve the developmental trajectory for infants with severe early-life epilepsy.
AUTHOR CONTRIBUTIONS
Dr. Shellhaas co-conceived the study, acquired data, analyzed the data, and wrote the first draft of the manuscript. Dr. Wusthoff acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Tsuchida acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Glass co-conceived the study, acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Chu acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Massey acquired data and provided critical revision of the manuscript for important intellectual content. Dr. Soul acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Wiwattanadittakul acquired data and provided critical revision of the manuscript for important intellectual content. Dr. Abend acquired data, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content. Dr. Cilio co-conceived the study, reviewed and analyzed all genetic testing results, assisted with interpretation of the results, and provided critical revision of the manuscript for important intellectual content.
